The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bayer for its non-small cell lung cancer (NSCLC) candidate BAY 2927088.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,